Recurrent Prostate Carcinoma (DBCOND0030423)

Identifiers

Synonyms
Not Available

Associated Data

Indicated Drugs and Targets
Not Available
Clinical Trials
IdentifierTitleDrug(s)PurposePhaseStatus
NCT06650579
REVELUTION-2: Relugolix+Abiraterone Acetate (AA) Versus Leuprolide+AA Cardiac TrialNo drug interventionstreatment3not_yet_recruiting
NCT06630325
A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced, Recurrent Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancertreatment2not_yet_recruiting
NCT02465060
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)screening2active_not_recruiting
NCT04514484
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIVtreatment1active_not_recruiting
NCT05779943
Comparison of 18F-rhPSMA-7.3 PET/CT With and Without Furosemide in Biochemical Recurrence of Prostate Cancerdiagnostic2active_not_recruiting
NCT02099864
Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapytreatment2active_not_recruiting
NCT02985021
Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficienciestreatment2terminated
NCT04857502
99mTc-PSMA-I&S Biodistribution in Patients With Prostate CancerNo drug interventionsbasic_science0recruiting
NCT04519879
White Button Mushroom Sup for the Reduction of PSA in Pts With Biochemically Rec or Therapy Naive Fav Risk Prostate CANo drug interventionstreatment2recruiting
NCT01638533
Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunctiontreatment1active_not_recruiting
NCT02673151
68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatmentdiagnostic2 / 3completed
NCT03902951
Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancertreatment2active_not_recruiting
NCT02935205
Enzalutamide and Indomethacin in Treating Patients With Recurrent or Metastatic Hormone-Resistant Prostate Cancertreatment1 / 2recruiting
NCT01251861
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancertreatment2active_not_recruiting
NCT05722288
Time-Restricted Eating Versus Nutritional Counseling for the Reduction of Radiation or Chemoradiation Tx Side Effects in Patients With Prostate, Cervical, or Rectal CancersNo drug interventionssupportive_care2recruiting
NCT00108732
A Phase II Study of PROSTVAC-V (Vaccinia)/TRICOM and PROSTVAC-F (Fowlpox)/TRICOM With GM-CSF in Patients With PSA Progression After Local Therapy for Prostate Cancertreatment2completed
NCT04457232
Prospective Exploratory Study of FAPi PET/CT in Prostate Cancer With Histopathology ValidationNo drug interventionsbasic_science1active_not_recruiting
NCT02420652
Metformin Hydrochloride and Aspirin in Treating Patients With Hormone-Dependent Prostate Cancer That Has Progressed After Surgery or Radiation Therapytreatment2terminated
NCT00936975
Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone MetastasesNo drug interventionsdiagnostic2completed
NCT03698370
Gallium Ga 68 DOTA-NeoBOMB1 and Gallium Ga 68 PSMA-R2 PET/MRI in Diagnosing Participants With Recurrent Prostate CancerNo drug interventionsdiagnostic2completed
NCT01120236
Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancertreatment2completed
NCT02646319
Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutationstreatment0completed
NCT02499835
Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancertreatment1 / 2completed
NCT00170157
Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancertreatment2completed
NCT02312557
Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamidetreatment2active_not_recruiting
NCT02228265
Molecular Features and Pathways in Predicting Drug Resistance in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving EnzalutamideNot AvailableNot Availablecompleted
NCT03582774
Multicenter Randomized Trial of 68Ga-PSMA-11 PET/CT Based SRT After Radical ProstatectomyNo drug interventionsdiagnostic3active_not_recruiting
NCT01522820
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumorstreatment1completed
NCT00064129
Ipilimumab and Sargramostim in Treating Patients With Metastatic Prostate Cancertreatment1completed
NCT03501940
F18 DCFPyL PET/CT in Imaging Participants With Recurrent Prostate CancerNo drug interventionsNot AvailableNot Availableno_longer_available
NCT03796767
Salvage Oligometastasectomy and Radiation Therapy in Recurrent Prostate CancerNo drug interventionstreatment2active_not_recruiting
NCT01050504
Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial CancerNo drug interventionsNot AvailableNot Availablerecruiting
NCT01576172
Abiraterone Acetate and Prednisone With or Without Veliparib in Treating Patients With Metastatic Castration-Resistant Prostate Cancertreatment2completed
NCT01519414
Tivantinib in Treating Patients With Metastatic Prostate Cancertreatment2completed
NCT01145508
Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancertreatment2terminated
NCT03122743
Collection of Serum Samples in Studying Emotional Stress in Patients With Prostate CancerNo drug interventionsNot AvailableNot Availablecompleted
NCT02899221
Hyperthermia and High Dose Rate Radiation Therapy in Treating Patients With Recurrent Prostate Cancer After RadiationNo drug interventionstreatmentNot Availableactive_not_recruiting
NCT03515577
Gallium Ga 68-labeled PSMA-11 PET/CT and Fluciclovine F18 PET/CT in Imaging Participants With Recurrent Prostate Cancer After Surgerydiagnostic2completed
NCT02807805
Abiraterone Acetate, Niclosamide, and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancertreatment2active_not_recruiting
NCT03123978
Enzalutamide and Niclosamide in Treating Patients With Recurrent or Metastatic Castration-Resistant Prostate Cancertreatment1completed
NCT02522715
Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancertreatment1 / 2active_not_recruiting
NCT02488070
68Ga-PSMA PET/CT or PET/MRI in Evaluating Patients With Recurrent Prostate Cancerdiagnostic1 / 2completed
NCT02881242
Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancertreatment2active_not_recruiting
NCT00486642
Pazopanib Hydrochloride With or Without Bicalutamide in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapytreatment2completed
NCT01253642
Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxeltreatment2terminated
NCT03016741
Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancersupportive_care4unknown_status
NCT02206334
Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate CancerNo drug interventionstreatment1completed
NCT01786265
Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancertreatment2active_not_recruiting
NCT01787331
Itraconazole in Treating Patients With Biochemically Relapsed Prostate Cancertreatment2completed
NCT05238831
SMMART Adaptive Clinical Treatment (ACT) Trialtreatment0withdrawn
NCT00536991
Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancertreatment1 / 2terminated
NCT05034562
Gallium-68 PSMA-11 PET in Participants With Prostate Cancerdiagnostic2withdrawn
NCT02940262
Gallium Ga 68-labeled PSMA-11 PET/CT in Detecting Recurrent Prostate Cancer in Patients After Initial TherapyNo drug interventionsdiagnostic3completed
NCT01503229
Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancertreatment2completed
NCT01953640
Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition TherapyNo drug interventionsNot AvailableNot Availableactive_not_recruiting
NCT04190446
Radiation Therapy (Hypofractionated Proton Beam Therapy or IMRT) for the Treatment of Recurrent, Oligometastatic Prostate Cancer Following Primary Localized TreatmentNo drug interventionstreatment2active_not_recruiting
NCT02532114
Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate Cancertreatment1completed
NCT02601014
Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7treatment2completed
NCT02159950
Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancertreatment2completed
NCT01026623
Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancertreatment1 / 2completed
NCT01833208
Radiation Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Receiving Sipuleucel-TNo drug interventionstreatmentNot Availablecompleted